The largest database of trusted experimental protocols

Magnetic activated cell sorting technology

Manufactured by Miltenyi Biotec
Sourced in United States

Magnetic-activated cell sorting technology is a method for separating and isolating specific cell populations from a heterogeneous sample. It utilizes magnetic beads coated with antibodies that bind to specific cell surface markers, allowing the targeted cells to be magnetically separated from the rest of the sample.

Automatically generated - may contain errors

6 protocols using magnetic activated cell sorting technology

1

Isolation and Culture of Mouse Renal Proximal Tubule Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Mouse renal proximal tubule cells (mRPTCs) were isolated from BALB/c mice kidneys using the Miltenyi Biotec's Magnetic‐Activated Cell Sorting technology. We used biotinylated Lotus tetragonolobus lectin (Vector #B‐1325) for the isolation of mRPTCs. The purity of the isolated cells was assessed by immunofluorescence staining using an antibody to SGLT2 (a marker protein of S1 and S2 segments of renal proximal tubule), as used previously.22 mRPTCs from C5Bl/6J mice were cultured from progenitor kidney cells isolated from mouse embryo kidneys of C57Bl/6J mice (kindly supplied by Dr. Ulrich Hopfer, Case Western Reserve University, School of Medicine), as reported by Woost et al.23
+ Open protocol
+ Expand
2

Isolation of CD133+CXCR4+ Endothelial Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD133+CXCR4+ EC cells were separated by Magnetic-Activated Cell Sorting technology (MACS; Miltenyi Biotec). Cultured EC cells at 70%–85% confluence were trypsinized by 0.25% trypsin and resuspended in cold (2–8 °C) MACS buffer (PBS [pH 7.2], 0.5% BSA, and 2 mM EDTA). Cells were stained with the CD133 FITC-conjugated primary antibody (Miltenyi Biotec) according to the manufacturer's recommendations. CD133 FITC-conjugated antibody was added per 107 total cells. The cells were then resuspended and 20 μL anti-FITC Multisort microbeads and 80 μL buffer were added per 107 total cells, mixed well, and incubated 15 min at 2–8 °C. The cells were then washed, applied to a column placed in the magnetic field of the MACS Separator (Miltenyi Biotec). For the second magnetic labeling and separation, 20 μL of MultiSort Release Reagent was added per 1 mL of cell suspension, Next, the MACS Micro Beads were added to magnetically label the cells for the second marker, the CXCR4 PE conjugated antibody (Beckman coulter, USA). The reaction was mixed well and incubated according to the manufacturer's recommendations.
+ Open protocol
+ Expand
3

Single-Cell RNA Sequencing of MGUS, SMM, and MM

Check if the same lab product or an alternative is used in the 5 most similar protocols
BM samples from patients with MGUS, SMM or MM, were collected as approved by the Dana-Farber Cancer Institute Institutional Review Board (protocols 14–174, 07–150, or 11–104). Informed consent was obtained from all patients in accordance with the Declaration of Helsinki protocol (fifth revision from 2000 with Clarifications of Articles 29, 30 (20022004), and the most recent iteration from 2013). MGUS and SMM patient samples were collected for a clinical trial, clinicaltrial.gov identifier NCT02269592. Samples from healthy donors were purchased from the company AllCells. CD138+ BM cell fractions were isolated using magnetic-activated cell sorting technology (Miltenyi Biotec). Selected cells were either viably cryopreserved in dimethylsulfoxide at a final concentration of 10% or used immediately for scRNA-seq.
+ Open protocol
+ Expand
4

Isolation of CD4+ T Cells from Blood

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood was drawn from healthy volunteers after informed consent. Lymphocyte separation medium was used to isolate lymphocytes and peripheral blood mononuclear cells ex vivo. Purified CD4+ T cells were separated from PBMCs by negative isolation using the magnetic-activated cell sorting technology (Miltenyi Biotec, USA).
+ Open protocol
+ Expand
5

Adoptive T Cell Transfer to RR22 Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells from the spleen and lymph nodes of ActbECFP reporter or Ccr9−/− mice were isolated by being passed through a steel wire mesh, filtered on a 40-μm cell strainer and after red blood cells lysis using ACK buffer. To enrich for T cells, single-cell suspensions were first incubated with biotin-conjugated anti-B220 (clone RA3-6B2; eBioscience), anti-CD19 (clone 1D3; eBioscience), anti-CD11b (clone M1/70; BD Biosciences), anti-CD11c (clone N418; eBioscience), anti-Gr1 (clone RB6-8C5; eBioscience); anti-NK1.1 (clone PK136; BD Biosciences) and anti-Ter119 (clone TER-119; BD Biosciences) antibodies followed by antibiotin microbeads (Miltenyi Biotec) and negatively selected by magnetic cell separation with magnetic-activated cell sorting technology (Miltenyi Biotec); 5 × 106 enriched T cells were intravenously transferred to Rag2−/−RorcGFPIl22TdT (RR22) mice; recipient mice were analyzed at day 14 post-transfer.
+ Open protocol
+ Expand
6

Purification of Human CD16 Monocyte Subsets

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMCs (peripheral blood mononuclear cells) were obtained by Ficoll density gradient (Nycomed Pharma) of buffy coats from healthy donors after signed informed consent. Human CD16 neg and CD16 pos Mo were purified by magnetic-activated cell sorting technology (Miltenyi Biotec), as reported previously [17] (link). Staining with anti-CD14 and anti-CD16 monoclonal antibodies showed >95 % CD16 neg Mo in the CD16 neg fraction and >85 % CD16 pos Mo in the CD16 pos fraction.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!